Embecta (NASDAQ: EMBC) to acquire Owen Mumford in up to £150m deal
Rhea-AI Filing Summary
Embecta Corp. has agreed to acquire UK-based medical device maker Owen Mumford Holdings Limited in a transaction valued at up to £150 million. Embecta will pay £100 million in cash at closing, plus up to £50 million in additional payments tied to net sales of the Aidaptus® auto-injector platform through the three-year period following closing.
Owen Mumford generated net revenue of £69.4 million during its fiscal year 2025 and brings a portfolio of drug-delivery and chronic care devices that complement Embecta’s diabetes-focused franchise. Embecta expects the deal to support revenue growth from fiscal year 2027 onward, be accretive to adjusted operating income after fiscal year 2027, and generate a high-single-digit return on invested capital by year four.
The transaction, unanimously approved by Embecta’s board, is structured as a share acquisition for 100% of Owen Mumford’s equity and is expected to close in Embecta’s fiscal third quarter of 2026, subject to regulatory approvals and customary conditions. Embecta plans to fund the upfront purchase price with borrowings under its revolving credit facility.
Positive
- Strategic expansion into drug delivery: Acquisition of Owen Mumford adds a differentiated auto‑injector platform (Aidaptus®) and chronic care devices that complement Embecta’s diabetes franchise and broaden its medical supplies portfolio.
- Growth and return profile: Management expects the deal to support revenue growth from fiscal year 2027 onward and to generate a high-single-digit return on invested capital by year four, with accretion to adjusted operating income after fiscal year 2027.
Negative
- Near-term earnings dilution: Embecta expects the transaction to be dilutive to adjusted net income in fiscal year 2027 before turning neutral to accretive in later years.
- Increased leverage from debt financing: The upfront £100 million cash payment will be financed with borrowings under the revolving credit facility, increasing debt ahead of realizing expected synergies and returns.
Insights
Embecta is buying Owen Mumford for up to £150 million to expand into drug-delivery devices, with benefits weighted to 2027 and beyond.
Embecta is acquiring Owen Mumford for an upfront £100 million in cash plus up to £50 million in performance-based payments linked to Aidaptus® auto-injector net sales. Owen Mumford generated net revenue of £69.4 million in fiscal year 2025, so the valuation reflects a strategic premium for its platform and intellectual property.
The deal targets growth in drug-delivery devices across obesity, diabetes, autoimmune diseases and anaphylaxis, leveraging Embecta’s global commercial footprint. Management expects the acquisition to contribute to revenue growth from fiscal year 2027, be immaterial to adjusted operating income in fiscal year 2027 and accretive thereafter, and reach a high-single-digit return on invested capital by year four.
Near term, the company guides to dilution to adjusted net income in fiscal year 2027 and plans to finance the upfront price via its revolving credit facility, increasing debt before synergies materialize. Subsequent company filings and the fiscal second quarter 2026 earnings call are indicated as forums for more detail on integration and financial trajectory.
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | ||
(Commission File Number) |
(IRS Employer Identification No.) | |
(Address of principal executive offices) |
(Zip Code) | |
| Registrant’s telephone number, including area code: ( | ||
| N/A (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
Title of each class |
Trading symbol(s) |
Name of each exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On March 19, 2026, Embecta Corp. (“embecta”) entered into a definitive Agreement for the Sale and Purchase of Owen Mumford Holdings Limited (the “Purchase Agreement”) with Mark Owen, Adam Mumford (in his individual capacity and in his capacity as trustee of the Mumford Family 2026 Trust), Anne Mumford (in her capacity as trustee of the Mumford Family 2026 Trust), Ellen Owen, Kim Priddis and Nancy Millington (together, the “Sellers”) pursuant to which embecta has agreed to acquire Owen Mumford Holdings Limited (“OM”), a privately held, UK-based innovator and manufacturer of medical devices and drug-delivery technologies, in a transaction valued at up to £150 million (the “Transaction”). Under the terms of the Purchase Agreement, embecta will acquire OM for an upfront cash payment of £100 million at closing (subject to customary adjustments, including for closing net cash), and will pay up to an additional £50 million upon the achievement of certain commercial milestones related to sales of the Aidaptus® next-generation auto-injector platform through the end of 2028. The Transaction was unanimously approved by the embecta Board of Directors and is expected to close in embecta’s fiscal third quarter of 2026.
Pursuant to the Purchase Agreement, the parties have made customary representations and warranties and agreed to various customary covenants, including, among others, covenants to conduct the business of OM and its subsidiaries in the ordinary course between the execution of the Purchase Agreement and the consummation of the Transaction and post-closing non-solicitation and non-competition covenants applicable to the sellers of OM.
The consummation of the Transaction is subject to customary closing conditions and regulatory approvals. There are no material relationships between embecta or its affiliates and the Sellers, other than with respect to the transaction described herein.
The foregoing description of the Purchase Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Purchase Agreement filed as Exhibit 2.1 hereto and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On March 19, 2026, embecta issued a press release announcing the entering into of the Purchase Agreement, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 2.1 | Agreement for the Sale and Purchase of Owen Mumford Holdings Limited, dated March 19, 2026, among Embecta Corp. and the Sellers listed in Schedule 1 thereto.* |
| 99.1 | Press Release, dated March 19, 2026. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Schedules and exhibits have been omitted pursuant to Instruction 4 of Item 1.01 of Form 8-K and Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 19, 2026 | EMBECTA CORP. | |
| By: | /s/ Jeff Mann | |
| Jeff Mann | ||
| Senior Vice President, General Counsel & Product Development, and Corporate Secretary | ||
embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited
Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad-based medical supplies company
PARSIPPANY, N.J., Mar. 19, 2026 -- Embecta Corp. (“Embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug-delivery technologies, in a transaction valued at up to £150 million. Under the terms of the agreement, embecta will acquire Owen Mumford for an upfront cash payment of £100 million at closing (subject to customary adjustments, including for closing net cash), and up to an additional £50 million in performance-based payments based on net sales of the Aidaptus® next generation auto-injector platform in the three-year period following the closing. The transaction was unanimously approved by the embecta Board of Directors and is expected to close in embecta’s fiscal third quarter of 2026, subject to regulatory approvals and satisfaction of other closing conditions.
Owen Mumford is an innovator in drug delivery platforms and medical device technologies, serving as a trusted partner to many of the world’s largest pharmaceutical, biotech and healthcare organizations. The company’s products include a rapidly growing pharmaceutical services portfolio built on historic autoinjector success with established pharmaceutical companies and an outlook anchored by Aidaptus® and other drug delivery devices. Owen Mumford pioneered the first plastic autoinjector and has continued to innovate and expand their product portfolio, specializing in the design and manufacture of drug delivery devices. Owen Mumford also has an established portfolio of medical devices across point-of-care testing, self-injection and pelvic health devices, with commercial channels, call points, customer relationships and geographic footprint that are highly complementary to embecta’s existing global diabetes care franchise and commercial infrastructure.
"We are extremely pleased to announce this agreement to acquire Owen Mumford, a company that has earned a global reputation for innovation, quality and patient-centered design," said Devdatt (Dev) Kurdikar, Chairman, President and CEO of embecta. "This acquisition is expected to sustainably improve embecta’s revenue growth trajectory and will accelerate our strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets."
"Owen Mumford has a 70-year track-record of developing innovative solutions with long-term growth potential," said Gavin Jones, Managing Director of Owen Mumford. "With our complementary portfolios and manufacturing expertise, and by leveraging embecta’s commercial scale, we will continue to drive innovation that improves the quality of life for people living with chronic conditions and other healthcare needs while creating new opportunities for our valued customers and the Owen Mumford team."
STRATEGIC AND EXPECTED FINANCIAL BENEFITS AND TRANSACTION DETAILS
Adds a differentiated drug-delivery platform designed to support pharmaceutical partners across multiple therapeutic areas and a strong underlying intellectual property portfolio. This includes Owen Mumford’s next-generation Aidaptus® auto-injector platform. Aidaptus® combines an innovative patient-centric design and novel technology delivering a device with clear features and benefits. With one form factor and a single final assembly process, it streamlines large-scale manufacturing while reducing changeovers and supply chain complexity.
Expands product portfolio of chronic care devices and creates an opportunity to capitalize on embecta’s commercial presence in more than 100 countries. During fiscal year 2025, Owen Mumford generated approximately 80% of its revenue in the UK and the U.S. This creates a meaningful opportunity to leverage embecta’s global commercial infrastructure, call points and robust distribution network to broaden geographic reach and further scale these products worldwide.
Leverages core manufacturing strengths in high volume medical products by combining Owen Mumford’s device design, molding and assembly capabilities in drug-delivery systems with embecta’s large-scale manufacturing expertise, creating opportunities for operational efficiencies and expanded capacity to support future product programs.
Transaction structure and financial rationale
The transaction is structured as a share acquisition in which embecta will acquire 100% of the shares of Owen Mumford for an upfront cash payment of £100 million payable at closing, subject to customary purchase price adjustments for closing net cash and working capital, and up to an additional £50 million in performance-based payments based on net sales of Aidaptus® in the three-year period following the closing.
Owen Mumford has a fiscal year end of September 30, and during fiscal year 2025, generated net revenue of £69.4 million.
embecta expects the acquisition to contribute to revenue growth in fiscal year 2027 and beyond; to be immaterial to embecta’s fiscal year 2027 adjusted operating income and to be accretive thereafter; to be dilutive to adjusted net income in fiscal year 2027, to be immaterial to embecta’s fiscal year 2028 adjusted net income and to be accretive thereafter; and to generate high-single-digit return on invested capital by year four, with increasing contribution thereafter.
The Company intends to discuss this acquisition in more detail on its upcoming fiscal second quarter 2026 earnings conference call, to be held on May 5, 2026.
Financing
embecta plans to finance the closing purchase price with the proceeds of borrowings under its revolving credit facility. Over the long term, embecta remains committed to paying down debt and creating financial flexibility.
Advisors
J.P. Morgan Securities LLC is serving as financial advisor and A&O Shearman LLP is serving as legal counsel to embecta.
Forvis Mazars LLP is serving as financial advisor and Mills & Reeve LLP is serving as legal counsel to Owen Mumford.
About embecta
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
About Owen Mumford
Founded in 1952 and headquartered in Oxfordshire, United Kingdom, Owen Mumford is a family-owned medical technology company with more than 70 years of innovation in healthcare device development. The company has built a strong reputation as a trusted partner to pharmaceutical and biotechnology companies, developing drug delivery technologies that support the administration of complex therapies, including its next-generation Aidaptus® auto-injector platform designed to enable future pharmaceutical partnerships. In addition to its drug delivery capabilities, Owen Mumford also offers a portfolio of medical devices used in chronic care and point-of-care applications, including self-injection, diagnostics and other patient-focused healthcare solutions distributed in markets around the world.
SAFE HARBOR STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding strategic direction and priorities and expectations regarding our acquisition of Owen Mumford. These forward-looking statements are subject to various known and unknown risks, uncertainties and other factors, and you should not rely upon them except as statements of our present intentions and of our present expectations, which may or may not occur. When we use words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “pursue,” “will,” “goal” or similar expressions, we are making forward-looking statements. Although we believe that our forward-looking statements are based on reasonable assumptions, our expected results may not be achieved, and actual results may differ materially from our expectations.
| 2 |
In addition, important factors
that could cause actual results to differ from expectations include, among others, the risks described in our periodic reports filed with
the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form
10-K, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter. Except as required by law, we undertake
no obligation to update any forward-looking statements appearing in this release.
| Contacts | |
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| Contact Media Relations | Contact IR |
3
FAQ
What acquisition did Embecta (EMBC) announce involving Owen Mumford?
How is the Embecta (EMBC)–Owen Mumford deal structured financially?
When is the Embecta (EMBC) acquisition of Owen Mumford expected to close?
What were Owen Mumford’s recent revenues cited by Embecta (EMBC)?
How will Embecta (EMBC) finance the Owen Mumford acquisition?
What financial impact does Embecta (EMBC) expect from the Owen Mumford deal?
Why is the Owen Mumford acquisition strategically important for Embecta (EMBC)?
Filing Exhibits & Attachments
5 documents